NGM Biopharmaceuticals: A Double Whammy Of NASH And GA Failure Hurt Its Stock
Seeking Alpha,
Follow Summary NGM failed both the NASH and GA trials. However, its oncology pipeline looks promising.
Late-stage melanoma: Experimental drug combo puts 50% of patients into…
Medical News Today,
Share on PinterestCould a two-drug combination improve treatment response in late-stage melanoma? Glasshouse Images…
Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire
Cancer Cell International,
Abstract Background Radiotherapy is a powerful and widely used technique for the treatment of solid tumors.
HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells
Cancer Cell International,
Abstract Background KRAS mutation accounts for 30–50% of human colorectal cancer (CRC) cases.